Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
DURUISSEAUX et al. 2017
The OS with XALKORI in unselected ALK+ NSCLC patients was assessed.1
Median OS of 89.6 months for patients receiving next-generation ALK inhibitors after progression on XALKORI was significantly longer than with XALKORI followed by other systemic therapies (28.2 months) or BSC (19.6 months) (p<0.001).1
Limitations of the analysis:1
The improved OS data may have been due to biases in patient selection, OR specific tumour biology and high sensitivity to ALK inhibition, rather than a direct effect of treatment strategies.
Patients receiving next-generation ALK inhibitors tended to be younger, more frequently exhibited PFS on XALKORI ≥median, more frequently received XALKORI beyond progressive disease, and more frequently exhibited cerebral progression than patients receiving subsequent drugs other than next-generation ALK inhibitors.
5.0% of patients received XALKORI in first line, 54.1% in second line and 40.9% in later lines of therapy (≥2).
Next-generation ALK inhibitors administered: 57 patients received ceritinib, 19 alectinib, 5 ceritinib then alectinib, 1 ceritinib then lorlatinib, 2 alectinib then ceritinib. Lorlatinib is an investigational compound.
The mean time from diagnosis of advanced disease to initiation of XALKORI was 13.9 months (95% CI: 12.4–15.5).
OS from diagnosis according to systemic treatments initiated following progression on XALKORI (n=263)*1
Adapted from Duruisseuax M, et al. Oncotarget, 2017;8(13):21903-17.1
*Median duration of follow-up was 44.4 months (95% Ci: 40.6-47.5).
ALK inhibitors1
The survival rates reported here in a large population treated with crizotinib then next-generation ALK inhibitors could represent an interesting benchmark for ongoing clinical trials assessing how best to sequence the available ALK inhibitors.
- Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–17.
- XALKORI Summary of Product Characteristics.
Real World Evidence
Indication
XALKORI as a monotherapy is indicated for:2
- The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
- The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
- The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Register to receive tailored information from Pfizer by email
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No